News

Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched. With fresh questions around obesity drug competition, patent risk and a changing leadership team, investors are weighing whether that discount is a warning sign or an opportunity. The share price has declined 51.9% over the past three years, which puts a clear spotlight on whether the current level already reflects the main concerns around...

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company’s growth trajectory. The stock fell more than 3% in Copenhagen trading Thursday.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.

Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust

The S&P 500 and Dow Jones hit highs while the Nasdaq raced above key levels as oil prices and yields fell. Palantir, Cloudflare and SpaceX were big movers amid earings.

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

Novo Nordisk lifts its 2026 outlook as Wegovy pill demand accelerates, even as U.S. pricing, patent losses and competition pressure the second half.

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

Novo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.

US stock futures edged higher on Wednesday as investors reacted to renewed hopes of easing tensions in the Middle East, while corporate earnings from SpaceX (NASDAQ:SPCX), Advanced Micro Devices (NASDAQ:AMD) and Novo Nordisk (NYSE:NVO) drove significant pre-market trading. Although geopolitical developments supported overall market sentiment, investors also assessed company-specific news, particularly Elon Musk’s latest comments, which weighed on both SpaceX and AMD shares.

August 5 (Reuters) - European shares rose on Wednesday as investors monitored corporate earnings and diplomatic efforts to end the U.S.-Iran war and reopen the blockaded Strait of Hormuz.

Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.

The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit

The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.

Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

Stocks rose in midday trading Friday, erasing earlier losses as investors assessed earnings from maj

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it more cautiously than the fundamentals imply. Over the past 3 years, Novo Nordisk has delivered a total shareholder return that is down 35.8%, which puts the recent share price in the context of a material drawdown for long term holders. Expectations around the obesity and diabetes franchise, including products such as Wegovy, sit alongside legal and...

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so

The company’s second upgrade to annual guidance is a sign that companies are scrambling for its semiconductor-making tools in the race to build AI infrastructure.

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.